Department of Head and Neck Surgical Oncology, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.
Department of Head and Neck Surgical Oncology, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia; Department of ENT Head & Neck Surgery, St Vincent's Hospital Melbourne, Melbourne, VIC, Australia.
Oral Oncol. 2022 Dec;135:106213. doi: 10.1016/j.oraloncology.2022.106213. Epub 2022 Oct 20.
Our objective was to determine the negative predictive value (NPV) of preoperative FDG PET/CTfor detecting locoregional nodal disease. The aim was to help inform the decision-making process when identifying patients with early-stage OPSCC that would be suitable for transoral robotic surgery (TORS) as a single-modality treatment.
A retrospective cohort study was conducted of adults with primary stage cT1-2 OPSCC with up to one metastatic neck lymph node (cN0-1) planned for TORS. Patients with a preoperative PET/CT and who had undergone staging neck dissection (ND) were included. Clinical and pathological nodal staging was established based on PET/CT and ND, respectively. The primary outcome was the frequency of occult (not seen on PET/CT) nodal disease on ND.
Eighty-eight patients were included (N = 88). The rate of occult nodal disease was 28.4 % (n = 25). The NPV of PET/CT in the clinically negative neck was 79 % and 66 % in cases with a single clinical node. Following staging ND, thetreatment plan changed in 27 % of cases overall, 7 % in cN0 and 36.7 % in cN1. Among these, 18 % met criteria for radiotherapy and 9 % for CRT. This represented a decrease in the number of ideal candidates for TORS as single-modality treatment from 88 to 64 (73 %).
PET/CT is a useful tool in the workup of patients for primary TORS. However, about one third of patients with early-stage OPSCC might benefit from adjuvant therapy not predicted by preoperative PET/CT. A staging ND helps confirm candidates for single-modality treatment with TORS.
我们的目的是确定术前 FDG PET/CT 检测局部区域淋巴结疾病的阴性预测值(NPV)。目的是帮助在确定适合经口机器人手术(TORS)作为单一模式治疗的早期 OPSCC 患者时,为决策过程提供信息。
对计划接受 TORS 的原发性 cT1-2 OPSCC 伴最多一个转移性颈部淋巴结(cN0-1)的成人进行了回顾性队列研究。纳入了术前 PET/CT 检查并接受了分期颈部清扫术(ND)的患者。临床和病理淋巴结分期分别基于 PET/CT 和 ND 确定。主要结局是 ND 上隐匿性(PET/CT 未见)淋巴结疾病的频率。
共纳入 88 例患者(N=88)。隐匿性淋巴结疾病的发生率为 28.4%(n=25)。临床阴性颈部的 PET/CT 的 NPV 为 79%,单一临床淋巴结的 NPV 为 66%。在接受分期 ND 后,总体治疗计划发生改变的病例占 27%,cN0 占 7%,cN1 占 36.7%。其中,18%符合放疗标准,9%符合 CRT 标准。这意味着作为单一模式治疗的理想 TORS 候选人数从 88 人减少到 64 人(73%)。
PET/CT 是原发性 TORS 患者检查的有用工具。然而,大约三分之一的早期 OPSCC 患者可能受益于术前 PET/CT 未预测的辅助治疗。分期 ND 有助于确认适合 TORS 单一模式治疗的候选者。